AstraZeneca and Daiichi Sankyo's Enhertu Receives EU Approval for First-Line Breast Cancer Combination Therapy
nashnova research
AstraZeneca and Daiichi Sankyo's ADC drug Enhertu has won EU approval for first-line breast cancer combination therapy, moving it from later-line use and significantly expanding the reachable patient population.
What exactly did the EU just approve?
Enhertu is an ADC — an antibody-drug conjugate that attaches a chemotherapy payload to an antibody, so the drug homes in on cancer cells and releases its toxin there, sparing healthy tissue.
The European Commission approved it as a combination therapy for certain breast cancer patients at the first-line stage.
This means → doctors can now prescribe Enhertu from the very start of treatment, rather than waiting until other options have failed.
Why does "first-line" versus "later-line" matter?
Previously, Enhertu was approved only for later-line treatment — a fallback after other therapies stopped working.
A first-line approval puts it on the front page of the treatment menu; the eligible patient pool is far larger.
In plain terms = it went from "use me after everything else fails" to "use me right away."
What does this mean for AstraZeneca and Daiichi Sankyo?
Enhertu is the flagship product of the two companies' ADC partnership, already approved in multiple markets for breast cancer and other solid tumours.
The EU first-line nod is a major commercialisation milestone — first-line markets offer a larger patient base and longer treatment cycles than later lines.
This reflects growing regulatory confidence in the ADC approach, moving it from "supplementary option" toward "standard of care."
市场有风险，内容仅供研究参考，不构成投资建议。